Astria Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) announced that CEO Jill C. Milne, Ph.D., will present an overview of the company and its lead program, STAR-0215, which targets hereditary angioedema (HAE), at two upcoming virtual investor conferences. The presentations will take place at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, and the Oppenheimer Fall Healthcare, Life Sciences, and MedTech Summit on September 22, 2021. Webcasts can be accessed through Astria's investor section on their website and will be available for 30 days post-event.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the following upcoming virtual investor conferences:

• H.C. Wainwright 23^rd Annual Global Investment Conference on September 13, 2021. The on-demand presentation will be available at 7:00am ET at the following link: https://journey.ct.events/view/5b3d4715-8ae5-4b39-9000-ba72d0444848
• Oppenheimer Fall Healthcare, Life Sciences, and MedTech Summit on September 22, 2021. The presentation will be available at 2:55pm ET at the following link: https://wsw.com/webcast/oppenheimer16/catb/2735278

Webcasts of the events can be accessed from the investors section of www.astriatx.com. Archived replays will be available for 30 days following the event.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005022/en/

Astria:



Investor relations:

Andrea Matthews

investors@astriatx.com



Media:

Elizabeth Higgins

media@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

What is Astria Therapeutics presenting at the H.C. Wainwright conference on September 13, 2021?

Astria Therapeutics will provide a corporate overview and information on its lead program, STAR-0215.

When is the Oppenheimer Fall Healthcare Summit where Astria Therapeutics will present?

The Oppenheimer Fall Healthcare Summit is scheduled for September 22, 2021.

What is STAR-0215 developed by Astria Therapeutics?

STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein aimed at treating hereditary angioedema.

Where can I watch Astria Therapeutics' presentations?

Webcasts of the presentations can be accessed from the investors section of Astria Therapeutics' website.

How long will the webcasts of Astria Therapeutics' presentations be available?

The archived replays of the webcasts will be available for 30 days following each event.